Yeji

$JAZZ

Jazz Pharmaceuticals plc

Runway:cash-flow +
NasdaqMarket cap: —CIK 0001232524

Upcoming catalysts

1 surfaced
NDA/BLA filedDate TBD
$JAZZJazz Pharmaceuticals plc
dordaviprone · recurrent H3 K27M-mutant diffuse glioma (accelerated approval)
“A New Drug Application (NDA) for accelerated approval of dordaviprone in recurrent H3 K27M-mutant diffuse glioma was recently accepted and granted Priority Review by FDA.”

Drug pipeline

zepzelca
ziihera
xywav
epidiolex
rylaze
vyxeos
lumryz
cataplexy or excessive daytime sleepiness (EDS) in adult patients with narcolepsy
dordaviprone
recurrent H3 K27M-mutant diffuse glioma (accelerated approval)
Sativex®
Spasticity
Asparaginase Erwinia Chrysanthemi (recombinant)
Acute Lymphoblastic Leukemia
Placebo
Epilepsy
GWP42003-P
Epilepsy
ODSH
Acute Myeloid Leukemia
IM JZP-458
Acute Lymphoblastic Leukemia
CMX157
Healthy
Xyrem®
Fibromyalgia
JZP258
Narcolepsy
CPX-351
Acute Myeloid Leukemia With Myelodysplasia-Related Changes
CMX001
Hepatic Impairment
GWP42003-P 20 mg/kg/day Dose
Epilepsy
Rapydan
Healthy
GWP42003
Dyslipidemias
Sativex
Pain
Placebo spray and oral moxifloxacin placebo
Effects of Sativex on ECG
JZP-110
Obstructive Sleep Apnea
Dociparstat sodium
Acute Myeloid Leukemia
Defibrotide
Veno-occlusive Disease
Cannabidiol Oral Solution [Epidiolex]
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
Nabiximols
Pain
GWP42004
Diabetes Mellitus, Type 2
Zanidatamab
Breast Cancer
ODSH at 0.125 mg/kg/h
Protein Losing Enteropathy
Transition from Xyrem to Xywav
Narcolepsy
Caphosol
Oral Mucositis
Cannabidiol
Lennox Gastaut Syndrome
Nab paclitaxel
Metastatic Pancreatic Cancer
Ziconotide
Patients With Severe Chronic Pain
Open-Label
Chronic Obstructive Pulmonary Disease
GWP42006
Autism Spectrum Disorder
pegcrisantaspase
Acute Lymphoblastic Leukemia
Epidiolex 100 mg/mL Oral Solution
Lennox Gastaut Syndrome
JZP341
Advanced Solid Tumor
Xyrem (sodium oxybate) oral solution
Fibromyalgia
Dordaviprone (ONC201)
Glioma
experimental anti-anxiety drug
Anxiety Disorder
Vyxeos liposomal
Acute Myeloid Leukemia (AML)
JZP815
Advanced Cancer
Dociparstat
Acute Myeloid Leukemia
CPX-351 (Cytarabine:Daunorubicin) Liposome Injection
Hematologic Neoplasms
asparaginase Erwinia chrysanthemi
Acute Lymphoblastic Leukemia

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06113237epidiolex—Recruiting2033-08-31
NCT07282587—Phase 2Recruiting2028-12-15
NCT06282575ZanidatamabPhase 3Recruiting2028-12-01
NCT07533942—Phase 2Not Yet Recruiting2028-10-25
NCT05580562Dordaviprone (ONC201)Phase 3Recruiting2028-06-01
NCT06435429ZanidatamabPhase 3Recruiting2028-04-28
NCT05557045JZP815Phase 1Recruiting2028-04-01
NCT07459634—Phase 2Not Yet Recruiting2028-01-31
NCT05734066—Phase 2Recruiting2028-01-28
NCT07102381ZanidatamabPhase 2Recruiting2028-01-01
NCT07625280xywavPhase 3Not Yet Recruiting2027-12-23
NCT06108050—Phase 1Recruiting2027-11-30
NCT07233239—Phase 1Recruiting2027-11-29
NCT05044819CannabidiolPhase 4Active Not Recruiting2027-08-01
NCT05485831Epidiolex 100 mg/mL Oral Solution—Active Not Recruiting2027-02-01
NCT06695845ZanidatamabPhase 2Recruiting2026-12-31
NCT05152147ZanidatamabPhase 3Active Not Recruiting2026-07-31
NCT07377539—Phase 1Recruiting2026-07-05
NCT05772429epidiolex—Active Not Recruiting2026-07-01
NCT04541082—Phase 1Recruiting2026-07-01

Recent catalysts

FDA approvalJan 27, 2026· 130d ago· success
$JAZZJazz Pharmaceuticals plc
vyxeos
“openFDA SUPPL (EFFICACY) approval of VYXEOS — application NDA209401”
FDA approvalOct 2, 2025· 247d ago· success
$JAZZJazz Pharmaceuticals plc
zepzelca
“openFDA SUPPL (EFFICACY) approval of ZEPZELCA — application NDA213702”
PDUFAAug 18, 2025· 292d ago
$JAZZJazz Pharmaceuticals plc
dordaviprone · recurrent H3 K27M-mutant diffuse glioma (accelerated approval)
“FDA has set a target Prescription Drug User Fee Act (PDUFA) action date of August 18, 2025.”
FDA approvalNov 20, 2024· 563d ago· success
$JAZZJazz Pharmaceuticals plc
ziihera
“openFDA ORIG (TYPE 1) approval of ZIIHERA — application BLA761416”
FDA approvalOct 20, 2023· 960d ago· success
$JAZZJazz Pharmaceuticals plc
epidiolex
“openFDA SUPPL (EFFICACY) approval of EPIDIOLEX — application NDA210365”
FDA approvalMay 1, 2023· 1132d ago
$JAZZJazz Pharmaceuticals plc
lumryz · cataplexy or excessive daytime sleepiness (EDS) in adult patients with narcolepsy
“Jazz Pharmaceuticals, Inc. ... filed a complaint in the United States District Court for the District of Columbia ... seeking a declaration that the U.S. Food and Drug Administration's ("FDA") approval on May 1, 2023 of the New Drug Application ("NDA") for Lumryz TM , an extended-release reformulation of Jazz's high sodium oxybate product Xyrem®, for the treatment of cataplexy or excessive daytime sleepiness ("EDS") in adult patients with narcolepsy, was unlawful.”
FDA approvalNov 18, 2022· 1296d ago· success
$JAZZJazz Pharmaceuticals plc
rylaze
“openFDA SUPPL (EFFICACY) approval of RYLAZE — application BLA761179”
FDA approvalSep 27, 2022· 1348d ago· success
$JAZZJazz Pharmaceuticals plc
vyxeos
“openFDA SUPPL (EFFICACY) approval of VYXEOS — application NDA209401”
FDA approvalAug 12, 2021· 1759d ago· success
$JAZZJazz Pharmaceuticals plc
xywav
“openFDA SUPPL (EFFICACY) approval of XYWAV — application NDA212690”
FDA approvalJun 30, 2021· 1802d ago· success
$JAZZJazz Pharmaceuticals plc
rylaze
“openFDA ORIG (TYPE 1) approval of RYLAZE — application BLA761179”